학술논문

Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques
Document Type
article
Source
Science Translational Medicine. 14(657)
Subject
Medical Microbiology
Biomedical and Clinical Sciences
Immunology
Vaccine Related
Pneumonia & Influenza
Emerging Infectious Diseases
Biotechnology
Biodefense
Prevention
Immunization
Vaccine Related (AIDS)
Pneumonia
Lung
Infectious Diseases
Infection
Good Health and Well Being
Animals
Antibodies
Neutralizing
Antibodies
Viral
Broadly Neutralizing Antibodies
COVID-19
Epitopes
Humans
Macaca mulatta
SARS-CoV-2
Spike Glycoprotein
Coronavirus
Biological Sciences
Medical and Health Sciences
Medical biotechnology
Biomedical engineering
Language
Abstract
To prepare for future coronavirus (CoV) pandemics, it is desirable to generate vaccines capable of eliciting broadly neutralizing antibody responses to CoVs. Here, we show that immunization of macaques with SARS-CoV-2 spike (S) protein with a two-shot protocol generated potent serum receptor binding domain cross-neutralizing antibody responses to both SARS-CoV-2 and SARS-CoV-1. Furthermore, responses were equally effective against most SARS-CoV-2 variants of concern (VOCs) and some were highly effective against Omicron. This result contrasts with human infection or many two-shot vaccination protocols where responses were typically more SARS-CoV-2 specific and where VOCs were less well neutralized. Structural studies showed that cloned macaque neutralizing antibodies, particularly using a given heavy chain germline gene, recognized a relatively conserved region proximal to the angiotensin converting enzyme 2 receptor binding site (RBS), whereas many frequently elicited human neutralizing antibodies targeted more variable epitopes overlapping the RBS. B cell repertoire differences between humans and macaques appeared to influence the vaccine response. The macaque neutralizing antibodies identified a pan-SARS-related virus epitope region less well targeted by human antibodies that could be exploited in rational vaccine design.